CANbridge Pharmaceuticals (HKG:1228) entered service procurement framework agreements with WuXi Biologics and Baheal Medical, according to a Tuesday Hong Kong bourse filing.
Under the agreement, WuXi Biologics (HKG:2269) will provide contract research, development, and manufacturing organization services to CANbridge through 2028.
Meanwhile, Baheal Medical will provide logistics, warehousing, and other supporting services through 2028.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.